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Abstract: Since a unique matrix tablet formulation that independently controls the release of 
various drug types is in a great demand, the objective of this research was to develop a sustained 
release matrix tablet as a universal dosage form using a binary mixture of the salt forms of 
Eudragit polymers rather than their interpolyelectrolyte complexes. Tablets were prepared by wet 
granulation and compressed at different compression forces, depending on drug type. Dissolution 
tests were conducted using USP XXII rotating paddle apparatus at 50 rpm at 37°C in consecutive 
pH stages. Tablets containing Ibuprofen (IB) as a model acidic drug and Metronidazole (MD) as 
a model basic drug showed controlled/sustained release behavior. For IB tablets containing 80% Ibuprofen 
and 5% (w/w) polymeric combination; the time for 50% of the drug release was about 24 hours compared to 
8.5 hours for plain tablets containing 80% IB. In case of MD, the drug release extended to about 7 hours for 
tablets containing 80% MD and 5% (w/w) polymeric combination, compared to about 1 hour for plain tablets 
containing 80% MD. In terms of extending the release of medications, the dissolution profiles of the tablets 
containing polymeric salts forms were found to be statistically superior to tablets prepared by direct 
compression of the polymers in their powdered base forms, and superior to tablets containing the same 
polymers granulated using isopropyl alcohol. The findings indicated the significance of combining the 
polymers in their salt forms in controlling the release of various drug types from matrices. 
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1. INTRODUCTION 
1.1. Eudragit® polymers proved to be suitable for wide 
variety of pharmaceutical applications such as film-coating 
agents for protective purposes and to provide sustained-
release formulations [1-6], and as binders in both aqueous 
and organic wet granulation processes [7]. Eudragit E (EE); 
is a cationic polymer based on dimethylaminoethyl 
methacrylate and neutral methacrylic acid esters that is 
soluble in gastric fluid as well as in weakly acidic buffer 
solutions up to pH 5 [1]. 
With a pK of 7.0–7.3 [8], EE would be partially protonated 
at pH close to 5; therefore an electrostatic interaction with 
another ionized polymers/drugs at this pH could contribute 
to extend drug release and impact its behavior [9, 10]. 
Eudragit L (EL) and Eudragit S (ES (are resistant to gastric 
fluids [11-13], but soluble in neutral to weakly alkaline 
conditions (pH 6-7) and form salts with alkalis. EL and ES  
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are anionic copolymers based on methacrylic acid and 
methyl methacrylate. Both EL and ES enjoy similar 
physicochemical properties except that the ratio of free 
carboxyl groups to the ester is approximately 1:1 in EL and 
approximately 1:2 in ES [3].  
         The polyelectrolytic nature of Eudragit® polymers was 
utilized by some researchers in the formation of 
interpolyelectrolyte complexes (IPECs) to control the release 
of certain drugs [9, 10, 14-17]. Interpolymer complexes are 
generally obtained by noncovalent interaction between 
oppositely charged polymers [18-26], and the drug plays 
mainly a passive role [27].  
        On the other hand, the use of mixtures of anionic and 
cationic polymethacrylate polymers rather than the use of 
their interpolyelectrolytic complex (IPEC) has been recently 
employed in our laboratory in order to control the release of 
neutral model drug Paracetamol. Tablets containing a 
combination of EE-citrate and EL-Na at 1:1 ratio and at 5-
12% w/w total polymeric contents were found effective in 
controlling the release of Paracetamol in sustained manner, 
which suggested the presence of certain specific interaction 
between EE-citrate and EL-Na with characteristics different 
from those of the individual polymers in their base forms 
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[28] and different from their interpolyelectrolytic complex 
(IPEC) [29]. However, since it was claimed in that earlier 
work that such combinations of polymers in their salt forms 
[individual granules] could have the potential to be 
employed as a universal carrier to control/sustain the release 
of drugs with different physicochemical properties, it was 
the aim of the current study to evaluate the behavior of acidic 
Ibuprofen (IB), and basic Metronidazole (MD) model drugs 
when incorporated in the same carrier system. Therefore, the 
release behavior of these model drugs from matrices 
containing mixtures of anionic and cationic polymethacrylate 
polymers (in their salt forms) are investigated and compared 
to matrices containing similar polymers in their base forms. 
IB is a non-steroidal anti-inflammatory drug available in 
doses ranging from 200 to 800 mg, and exhibits a pH 
solubility dependence due to its weakly acidic properties 
(pka 4.91) [30], while MD is an anti-infective agent available 
in doses ranging from 250 to 750 mg and exhibits a pH 
solubility dependence due to its weakly basic properties (pka 
2.62) [30]. For convenience, the chemical structures of 
model drugs and polymers employed in this study are shown 
in Figure 1. 
 
Insert Figure 1 here 
 
2. MATERIALS AND METHOD 
2.1. Materials 
The different types of Eudragit® polymers of various grades 
(Eudragit® E100, Eudragit® L100, and Eudragit® S100) were 
obtained from Evonik Industries AG Germany.  Methocel® 
E5, which is a low-viscosity grade of hydroxyl-propyl 
methyl-cellulose (HPMC), was obtained from Colorcon-
USA. Monobasic potassium phosphate, tri-basic sodium 
phosphate, sodium hydroxide were obtained from Scharlau-
Spain. Hydrochloric acid 37% and potassium bromide 
(UVasol®) for FTIR spectroscopy were provided by Merck-
Germany. Isopropyl alcohol (IPA) was obtained from Tedia-
USA. Phosphoric acid 85% was provided by Riedel-de 
Haen-Germany. Lactose monohydrate, magnesium stearate, 
and talc were obtained from Hikma Pharmaceutics-Jordan. 
Ibuprofen and Metronidazole were kindly provided by 
Jordan Pharmaceutical Manufacturing (JPM, Amman, 
Jordan). 
 
2.2. Methods 
2.2.1. Preparation of tablets  
Plain IB formulations were prepared by blending IB with 
lactose for four minutes, then magnesium stearate and talc 
were added and blended for one minute and the final blend 
was then compressed into tablets. Plain MD formulation 
were prepared similarly except for an additional component 
(Methocel E5) added in the first four minutes of mixing. 
Methocel E5 was added to aid producing MD tablets at a 
relatively lower compression force. Similar procedure was 
followed for preparation of tablets containing single, or 
binary (1:1 ratio) Eudragit® polymers in their powdered base 
forms. 
Tablets containing polymeric granules were prepared by 
manual blending of the individual model drugs (IB or MD) 
with lactose using a mortar and a pestle followed by gradual 
addition of a specified amounts (3-5 g, depending on 
formulation) of binder solutions while mixing until an 
adequate degree of agglomeration was visible in the dumpy 
mass. The following Eudragit® solutions were prepared for 
preparation of granules: for binder solutions containing 
polymeric salts, a specific amount of EE was dissolved in 1 
N hydrochloric solution, and specific amounts of EL or ES 
were dissolved in 1 N NaOH. Additionally, tablets 
containing polymeric granules in their non-salt forms were 
prepared by granulation using isopropyl alcohol (IPA) as a 
binder solution. Once a dumpy mass was produced, it was 
directly sieved into wet granules. The granules were then 
dried for 30 minutes in an oven at 50 °C followed by sifting 
the granules through different sieves (3, 2 and 1 mm aperture 
size). The moisture content of the dried granules was 
calculated using Halogen moisture analyzer (Model HR 85 
Halogen Mettler, USA) and was about 1.246- 1.862%.  
Tablets containing single, or binary (1:1 ratio) polymeric salt 
were prepared. In case of MD, Methocel E5 was added along 
with magnesium stearate and talc and blended with the 
granules for one minute and the final mixture was then 
compressed into tablets. All tablets were compressed using 
flat-faced, 13 mm diameter punches and die on a hydraulic 
single press (Carver®, USA). IB containing tablets were 
compressed at 500 kg for 30 seconds, while MD containing 
tablets were compressed at 5000 kg for 30 seconds to yield 
compacts of sufficient strength. The amounts of the model 
drug, lactose, and Methocel (in case of Metronidazole 
tablets) for each tablet were kept constant. Magnesium 
stearate and talc were used for lubrication at 0.25% w/w 
each. The tablets were produced at room temperature 
between 23 and 27 °C with the relative humidity between 37 
and 42%. Approximately 30 tablets were manufactured at 
each level of compression force and tablets were stored in 
airtight containers for at least 24 hours at room temperature 
to allow for consistent stress relaxation and hardening of the 
tablets. For each formula, mostly the aimed average tablet 
weight was 500 ±10 mg (except in certain formulations) and 
the average amount of active ingredient per tablet was 400 
mg ±5 mg. 
Tables 1a and 1b show the composition of the tablets 
containing IB prepared by direct compression of powders or 
by wet granulation, respectively. The composition of tablet 
formulations containing MD prepared by direct compression 
of powders or by wet granulation methods are shown in 
Tables 2a and 2b, respectively. The polymers concentrations 
in wet granulation method were determined by adding the 
specified amounts of polymeric solutions (in grams) to the 
drug and diluent.  
 
Insert Tables 1a, 1b, 2a, and 2b here. 
 
2.2.2. Dissolution studies 
         Dissolution tests were performed using Copley USP 
paddle dissolution apparatus II (Copley 10000, UK) 
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described in USP XX II (Apparatus II). The rotating speed 
was 50 rpm and the temperature was 37 ± 0.5 °C.  The 
release of the drug was investigated at 3 different stages that 
mimic the different pH values of the gastrointestinal 
environment; the first stage lasted for one hour at pH 1.2 
±0.2 and the volume of the dissolution medium was 500 ml. 
The second stage was conducted at pH 4.8 ±0.2 for 2 hours. 
The volume of the dissolution medium in the second stage 
was increased to 740 ± 5 ml by adding tribasic sodium 
phosphate (0.2 M Na3PO4) solution. The final stage was 
conducted from 5 to 24 hours and the pH was adjusted to 6.8 
±0.2 by adding (0.2 M Na3PO4) and completing the volume 
of the dissolution medium to 1000 ml. In addition, 
dissolutions of certain tablets formulations were conducted 
in media of constant pH values 1.2 ±0.2 and 6.8 ±0.2. In all 
cases, samples of 5 milliliters were withdrawn at appropriate 
time intervals, and replaced with an equal volume of fresh 
dissolution medium. Samples were filtered, diluted, and 
analyzed spectrophotometrically at the suitable λmax for each 
drug. Three tablets from each formulation were subjected to 
the dissolution test and the results were presented as the 
mean values of three determinations, standard deviation. The 
duration of the study ranged from 8-24 hours or until the 
cumulative drug release reached 90-100%. The percentage of 
drug released was plotted versus time.  
 
2.2.3. Physical tests 
2.2.3.1. Crushing strengths, thicknesses and diameters 
         Three tablets from each formula were tested for their 
crushing strengths using tablet hardness tester (Copley, 
2E/205/ Switzerland) in kilopond (Kp). The diameters and 
thicknesses for all tablets were determined using an 
electronic digital caliper (Digital Caliper 6``, Toolsnow, 
China) and the measurements were taken up to two decimal 
points.  
 
2.2.3.2. Stability study 
The stability in terms of drug release behavior of matrices 
containing model drugs and a combination polymeric salts 
was performed for short term (3 months) at room 
temperature. In addition, an accelerated stability test at 50°C 
was performed for 5 days.  
 
2.2.3.3. Differential Scanning Calorimetry Analysis 
         Differential scanning calorimetry (DSC) traces of plain 
Ibuprofen as well as plain Metronidazole powders, plain 
polymers, and physical mixture of Ibuprofen with the 
polymers, were recorded using a Shimadzu DSC-50 (Japan). 
Samples of approximately 5-8 mg were heated from 25 to 
250°C at 10°C/min. Pierced Aluminium pans were used for 
all samples. Pure indium was used to calibrate the DSC. 
 
2.2.3.4. Fourier transform infrared analysis (FT-IR) 
         The interaction between EE and EL was studied using 
FT-IR spectroscopy. FT-IR spectra of pure EE and EL 
polymers, physical mix of EE and EL, and physical mixture 
of EE and EL granules were obtained using an FT-IR 
spectrophotometer (Model 8400S Shimadzu, Japan) using 
KBr as a reference. The scanning range was 450-4000 cm−1. 
Samples were dried at 40 °C for 24 hours before analysis. 
 
2.2.4 Area under the dissolution curves and statistical 
analysis 
         For each of the two formulations being compared, the 
areas under the dissolution curves for three tablets were 
calculated using the trapezoidal rule, and the mean area 
under the curve and its standard deviation were estimated. 
The ratio of the mean area under the curve of the test 
formulation to that of the reference (plain) formulation was 
calculated (i.e., mean of test to mean of reference). Student 
T-test was employed to compare the mean of the area under 
the curve of the test formulation to the mean area under the 
curve of the reference (plain) formulation, at level of 
significance of 0.05. The threshold for a difference was 
considered significant when p value ≤ 0.05. 
 
. 
3. RESULTS AND DISCUSSION 
3.1. Analytical method and Physical characterization of 
tablets 
         Throughout this study, the UV analysis for the drugs 
was carried out at the appropriate λmax after dilution of the 
samples when needed. The UV/VIS spectrophotometric 
scanning of Ibuprofen showed an appropriate absorbance at 
264 nm without shifting at various pH values. The 
appropriate absorbance value was also reported by the 
European Pharmacopoeia (Ph. Eur.) [31]. On the other hand, 
Metronidazole showed maximum absorbance at 275 nm in 
acidic medium (pH 1.2), and at 320 nm in the buffered 
medium (pH 6.8). The calibration curves for both IB and 
MD were linear in different dissolution media in various pH 
values with a correlation coefficient close to 0.9998. No 
significant UV/VIS interaction between the drugs and the 
polymers employed in tablets preparation at the adopted 
wavelengths.  
         Tablets crushing strengths in terms of kilopound (Kp) 
were reported in Table 3 for all IB and MD tablets 
formulations. Apparently, IB was found to produce compacts 
of sufficient strengths under lower compression forces (500 
Kg) compared to MD (5000 Kg). All tablets formulations 
were also evaluated for their thicknesses and diameters in 
terms of millimeters, and the results were reported in Table 
3. Tablet formulations (IB and MD formulations) showed 
similar diameters, but slightly higher thicknesses compared 
to the plain tablets (IB#1) or (MD#1), respectively.  
 
3.2. Tablet dissolution and drug release studies 
       Both model drugs suffer pH dependent solubility 
profiles. Preliminary results during pH dissolution profiles 
(from pH 1.2 to 6.8 through 4.8) revealed that plain IB 
tablets (IB#1) exhibited negligible drug release in the acidic 
medium (pH 1.2), low release at pH 4.8, and an increased 
release at pH 6.8. Inversely, MD tablets (MD#1) exhibited 
rapid dissolution in the acidic stage (pH 1.2), and slower 
dissolution at pH 4.8 and 6.8 (data not shown).          
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         An interaction in the form of plasticization or 
liquefaction was visually noticed within a week upon storage 
at room temperature when EE in its base form was mixed 
with IB powders to form tablets. This can be due to an acid-
base or an anion-cation interaction. Similar phenomena was 
reported for the interaction of EE with Enalapril Maleate 
[34], and with different anionic drugs [35, 36], and for the 
interaction of anionic drugs with cationic polymers 
containing amino groups [37-39]. However, when the salt 
form of EE was employed via granulation, no such 
interaction was observed and tablets were found stable upon 
storage. Freshly prepared tablets containing EE base (IB#2) 
or EEHCl (IB#10) exhibited approximately similar release 
rates of IB at pH values of 1.2 and 4.8 due to the low 
solubility of IB in these media. Nevertheless, EEHCl 
provided significant retardation of IB release from IB#10 
compared to EE base tablets IB#2 in the buffered dissolution 
stage at pH 6.8. This was evident when the areas under the 
dissolution profiles of both formulations were compared as 
shown in Table 4. This can be attributed to the influence of 
wet granulation using EEHCl as a binder solution where it 
forms a film layer around each substrate particle within the 
granule [40] or completely envelope the particles [41]; 
resulting in a barrier to drug release during dissolution. In 
addition, the aforementioned plasticization effect exhibited 
by IB#2 tablets due to the presence of EE base might have 
accelerated IB dissolution and release.  
 
Insert Table 4 here 
 
         Unlike IB, MD was found to be compatible with EE in 
both forms (EE base or EEHCl). When MD was directly 
compressed with 5% EE base (MD#2), or when MD was 
granulated using 5% EEHCl solution (MD#10), the release 
rates were modified to different extents, but insignificantly 
(p >0.05) compared to plain MD tablets devoid of EE (Table 
4).  Despite that both EEHCl and MD are positively charged 
with possible electrostatic repulsion existed during the acid 
dissolution stage, the observed reduction in drug release rate 
could be attributed to the effect of granulation and probably 
to the film barrier effect [40, 41].  
         Generally, IB tablets prepared using 5% EE granules 
(EEHCl) (IB#10) were found to result in a significant 
decrease in drug release rates compared to plain tablets, or 
compared to tablets containing EE base form (IB#2) during 
the buffer stage (pH 6.8) dissolution (p ≤0.05). Similar 
behavior was noticed for the dissolution profile MD tablets 
prepared using 5% EE granules (EEHCl) (MD#10) when 
compared to MD#2 tablets containing similar concentration 
of EE base instead (data not shown).  
         Generally, both EL and ES in their powdered base 
forms induced faster IB release from the respective 
formulations to various degrees depending on the polymer 
type and concentration within the tablet as shown in Figure 
1. This increase in drug release can be attributed to the fact 
that IB, EL or ES became ionized at pH 6.8; therefore, owing 
to possible electrostatic repulsion, faster diffusion of IB was 
obtained. Higher concentrations (10%) of EL powder (IB#4) 
or ES powder (IB#6) produced significant increase in drug 
release rates compared to lower concentrations (5%); (IB#3) 
or (IB#5), respectively. Also, the drug release enhancement 
effect due to ES powder was significantly more than the 
effects due to EL powder at similar concentrations as shown 
in Table 4.  
        The behavior of the salt forms of these polymers (ELNa 
and ESNa) was different. While, 5% of ELNa (IB#11) 
produced marked retardation in IB release rates, similar 
concentration (5%) of ESNa (IB#12) enhanced the release 
rates of IB compared to those from plain IB tablets (IB#1), 
as shown in Figure 2. However, tablets containing the 
polymers in their salt forms (IB#11 and IB#12) exhibited 
marked retardation in IB release compared to tablets with 
polymers in their base forms (IB#3 and IB#5). This can be 
attributed to the impact of granulation process on distributing 
and enveloping the polymeric binders around the drug and 
excipients [40, 41]. The behavior can also be attributed to the 
significantly lower crushing strengths of tablets containing 
powdered polymers (IB#3, 4, 5, and IB#6) compared to 
those formulated via granulation (IB#11 and IB#12) as 
shown in Table 3. 
 
Insert Table 4 here 
  
         In general, it can be observed from Figures 2 and 3 
that the use of EL in its base or salt forms resulted in more 
resistance to drug release from matrices compared to the use 
of ES in its base or salt forms. Tablets containing ES powder 
exhibited higher crushing strengths than those containing EL 
powder, while tablets containing the salt forms of EL or ES 
were nearly comparable (Table 3). Since ES is less ionized 
than EL in the buffered medium at pH 6.8 due to the lower 
number of free carboxylic acid groups in its structure, it was 
expected to be more capable of retaining the already 
dissociated form of IB in this medium. Therefore, it logical 
to anticipate  that other factors such as the nature and degree 
of polymer swelling and/or the magnitude of tablet porosity 
might have influenced such rapid release from ES-containing 
tablets.   
 
Insert Figures 2 and 3 here 
 
For the basic model drug Metronidazole, the same release 
profile as the MD plain tablets was obtained upon 
incorporation of up to10% EL or ES powders in the 
formulations as presented in Figure 4.  
 
Insert Figure 4 here 
 
However, when MD was granulated using 5 or 10% ELNa 
(MD#11 or MD#12), or using 5 or 10% ESNa (MD#13 or 
MD#14), significant retardations in MD release in all 
dissolution media were observed (p ≤0.05). An interaction 
between a cationic drug containing an amino group and a 
polymer with anionic pending groups, that is, carboxylic 
group, electrostatically [42-46] or by hydrogen bonding [47-
51] has been reported frequently. However, it seemed that 
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such interaction was insignificant in case of MD with EL or 
with ES since drug release retardation was experienced in 
tablets containing the salt forms of the polymers. Since the 
crushing strengths of tablets containing ELNa or ESNa at 5 
or 10% were comparable to those of tablets containing 5 or 
10% EL or ES powders, respectively, then the retardation 
induced by granulation using ELNa or ESNa polymers could 
be attributed to the effects of granulation and film formation 
[40, 41], rather to a specific drug-polymer interaction. It was 
noteworthy that both polymers (ELNa or ESNa) behaved 
similarly in terms of regulating the release of MD from their 
compressed granules. 
         When polymeric combination was used at 5% total 
polymeric salts concentration (w/w) instead of individual 
polymers, a more sustained release of IB was observed 
compared to plain IB tablets as it is evident in Figure 5. 
 
Insert Figure 5 here 
 
However, IB tablets prepared by granulation using the salt 
forms of the polymers, i.e. EEHCl : ELNa (IB#13) or 
EEHCl:ESNa (IB#14) at 1:1 ratio, exhibited a significantly 
more sustained release compared to tablets containing a 
binary combination the free polymers  in their powdered 
base forms of similar ratios and concentrations, (p ≤0.05). 
This trend was apparent regardless the tablets were prepared 
by direct compression (IB#7) or granulation (IB#9) using the 
free polymers combination.  
        During dissolution in the buffered medium at pH 6.8, 
IB will be ionized carrying a negative charge. It is also 
anticipated that certain amount of EEHCl would become 
deprotonated and precipitated, while ELNa or ESNa remain 
as such; negatively charged. It was demonstrated earlier that 
tablets containing EEHCl alone (IB#10) exhibited more 
retardation of IB release compared to tablets containing EE 
base alone (IB#2). It was also shown in Figure 3 that tablets 
containing ELNa salt alone (IB#11) produced a significant 
retardation in IB release rates. However, tablets containing 
the polymeric salts combination (IB#13 and IB#14) resulted 
in a significantly more retardation effects on IB release 
compared to tablets containing EEHCl alone (IB#10) or 
ELNa salt alone (IB#11). The behavior seemed to be 
additive at the first glimpse. However, this is not the case 
considering the retardation of IB release from tablets 
containing ESNa salt with EEHCl salt (IB#14) compared to 
the enhancement of IB release from those containing ES salt 
alone (IB#12). This peculiar behavior may provide more 
evidence of polymeric interactions rather than a simple 
additive effect. Therefore, the behavior of tablets containing 
a combination of the salt forms is attributed to a possible 
synergism due to certain interactions between the two 
polymeric salts upon dissolution. Moreover, it is this 
interaction between the two polymeric salts rather than the 
effect of granulation per se is believed to be responsible for 
the retardation in drug release as discussed earlier and 
illustrated in Figure 5.   
         Generally, similar behavior was noticed with regard to 
MD tablet formulations as shown in part in Figure 6. The 
polymeric salt combinations used in preparing MD#15 and 
MD#17 tablets resulted in significant lowering in MD 
release compared to MD#7 and 10% MD#8 tablets 
containing polymeric combinations in their free forms. It 
was observed from Figure 6 that the drug release rates have 
been significantly reduced in all consecutive dissolution 
stages.  
 
Insert Figure 6 here 
 
In the acidic medium at pH 1.2, MD and EEHCl are 
protonated with positive charges and thus, the possibility of 
electrostatic repulsion exists. Upon using polymeric salts 
combinations, the drug release rates during the acidic stage 
were significantly lower compared to those from MD#10 
containing EEHCl alone. This can only be attributed to the 
presence of the second polymer which is ELNa or ESNa and 
a possible polymeric interaction that is responsible for 
extending the MD release in this medium. During dissolution 
in buffered medium at pH 4.8, MD and the two polymers 
existed in two states; protonated and unprotonated ones to 
various extents. However, unlike in MD#7 containing the 
binary polymers in their base forms, the drug release rates 
were significantly reduced for MD#15 and MD#17where the 
polymers existed originally in their salt forms (MD#15 and 
MD#17). In the buffered medium at pH 6.8, MD and certain 
amount of EEHCl might became deprotonated and 
precipitated, while ELNa or ESNa remained ionized and thus 
negatively charged. It was observed in Figure 5 that tablets 
containing ELNa alone or ESNa alone resulted in a 
retardation of MD release from MD#11 and MD#13 (at 5% 
concentration). However, this retardation was significantly 
lower than that brought up by the synergistic action of 
polymeric salts combinations of similar total polymers 
concentrations (5%) during dissolution in this stage (pH 6.8). 
Again, this indicated the presence of certain interaction that 
might have taken place upon dissolution between polymeric 
salts combination that lead to such significant drug release 
retardation.  
 The dissolution behaviors of Ibuprofen (IB#13) and 
Metronidazole (MD#15) tablets made of polymeric salts 
combination in acidic (pH 1.2) as well as in buffered media 
(pH 6.8) shown in Figures 7 and 8 were in agreement with 
those shown in Figures 5 and 6; indicating the influence of 
such combination on drugs release patterns. In addition, 
tablets subjected to short term stability (3 months) at room 
temperature and to an accelerated stability test at 50°C for 5 
days, yielded statistically similar drug release behavior to 
those analyzed at room temperature at all times intervals in 
all the three dissolution media (p > 0.05).  
 
Insert Figures 7 and 8 here 
 
        Therefore, the results were in support of a possible 
interaction upon dissolution that was suggested earlier to 
control the release of neutral model drug Paracetamol from 
matrix systems [28, 29]. This was apparently due to the high 
degree of interactions that could be existed between the 
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ionized polymers where maximum level charge density was 
obtained. In addition, hydrogen bonding which implies a 
weaker interaction than electrostatic bond, might have taken 
place. For example, a complex between Naltrexone 
hydrochloride and Eudragit L was successfully obtained by 
hydrogen bond occurring among polar group of both 
molecules [48]. Also, hydrogen bond was used to prepare 
interpolymer complexes for pharmaceutical applications [49, 
51, 52].  
  
3.3. Drug release mechanism 
        Data curve fitting and simulation were analyzed using 
SigmaPlot software, version SPW 11 (Systat Software, Inc., 
Ca, USA). Models of the drug release were fitted to the drug 
release data obtained from the dissolution of certain 
polymeric combination tablets selected for convenience; 
IB#13 and MD#15 in both acidic (pH 1.2) and buffered (pH 
6.8) media. Korsmeyer–Peppas (the power law) model was 
found to have the best fit to the drug release data limited to 
60% release. [32, 33]: 
                                                    [1] 
Where Qt and Q∞ are the amounts of drug released at time t 
and at the end of dissolution test, respectively, k is a constant 
incorporating the properties of the macromolecular 
polymeric systems and the drug, and n is a kinetic constant 
that is used to characterize the transport mechanism. In the 
case of a cylindrical matrices such as tablets, n=0.45 
suggests that the release mechanism follows Fickian 
diffusion where n = 0.89 indicates a case II transport 
mechanism. A hybrid release mechanism where polymer 
swelling and erosion as well as drug diffusion all controls 
drug release from the matrices when n values between 0.45 
and 0.89 are obtained.    
       For IB# 13, the drug release data in acidic medium were 
not fitted since about 10% cumulative drug release was 
obtained throughout the dissolution time. However, in the 
buffered medium (pH 6.8), the power law model fitted the 
data with regression coefficient (R²) was 0.9987, the constant 
K was 0.0821, while n value was 0.8636. For MD#15 in the 
acidic medium, the regression coefficient, the constant K and 
n value were 0.9981, 4.6315 and 0.6041 respectively, 
whereas, in the buffered medium (pH 6.8), these values were 
0.9962, 1.1435 and 0.7073 respectively. Therefore, the n 
values for both formulations (IB#13 and MD#15) were 
between 0.45 and 0.89, indicating a combined mechanism of 
diffusion, polymer swelling and/or matrix erosion at later 
stages of dissolution process.  The drugs release rates in the 
respective media decreased with time which is attributed to 
the increase in the diffusional path length due to polymer 
relaxation and matrix swelling as well as drug depletion 
from the tablets (53).  
 
3.4. Differential Scanning Calorimetry Analysis 
         Figure 9 shows the DSC traces for plain Ibuprofen 
(IB), individual polymers (EL and EE), mixtures of IB and 
EL, mixtures of IB and EE at various ratios (1:1, 2:1 and 
1:2), and mixtures of IB and EEHCl at 1:1 ratio. Mixtures 
containing ES exhibited similar pattern as those containing 
EL, therefore were not shown here.  
 
Insert Figure 9 here 
 
IB exhibited a sharp endothermic peak at about 77 oC 
attributed to the melting of plain IB. It was apparent from the 
figure that a peak broadening or early melting occurred in 
the region of IB melting peak when combined with EE at the 
different ratios. As mentioned earlier, it was observed that IB 
tablets containing EE polymer exhibited softening process 
shortly after their manufacture. This can be attributed to an 
acid-base interaction between the acidic drug IB and the 
basic polymer EE that lead to plasticization or softening of 
the tablets. The endotherm of plain IB was found to exhibit 
broadening and shifting to lower temperatures upon mixing 
with EE base at different ratios, as confirmed by differential 
scanning calorimetry (DSC). The DSC thermograms for the 
dried granules containing IB and the polymer in its salt form 
at 1:1 ratio (IB:EEHCl) exhibited a sharp endotherm at 77oC. 
The slight peak broadening or early melting in the latter case 
is indicative of absence or significantly lower drug-polymer 
interactions and therefore, the compatibility of such 
combination. 
        The DSC thermograms for MD and polymeric 
combinations were also conducted (data not shown). MD 
exhibited a sharp endotherm at about 170 oC attributed to its 
melting. In contrast to the behavior of IB, MD did not 
exhibit significant interactions with any of the polymers 
employed in tablets formulations, including EE base. This 
was confirmed by both visual examinations as well as 
differential scanning calorimetry (DSC) results. The 
endothermic peak of MD was found to be preserved with 
slight lowering when combined with EE, EL, or when MD 
was granulated with EE/ 0.1N HCl solution. The slight 
lowering of MD melting point did not reveal any changes on 
the visual appearance of the tablets. Therefore, these results 
indicated the compatibility of MD with all employed 
polymers. 
 
3.5. Fourier transform infrared analysis (FT-IR) 
Figure 10 shows the FT-IR spectra of moisture-free 
pure EE and EL powdered polymers, EE and EL granules, 
physical mix of EE and EL at 1:1 ratio, and physical mix of 
EE and EL granules at 1:1 ratio. ES spectra exhibited similar 
pattern to EL, therefore were not shown here.  
 
Insert Figure 10 here 
 
Since EE and EL (or ES) are derivatives of methacrylic acid 
copolymers, the FT-IR spectra would exhibit many common 
features. EE showed characteristic band at 1728 cm-1 which 
corresponds to absorption of ester groups in addition to two 
more absorption bands at 2769 and 2823 cm-1 which 
corresponds to the optical absorption due to non-ionized 
dimethylamino groups. On the other hand, the spectrum of 
EL showed similar but broader absorption band for the non-
ionized carboxylic acid groups at 1728 cm-1 than that found 
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in EE due to the intra- and intermolecular hydrogen bonding 
between the carboxylic acid groups [54]. In addition, EL [or 
ES] also showed a wide absorption range of the associated 
hydroxyl groups between 2500 and 3500 cm-1 shown as 
several minor peaks. The FT-IR spectrum of the physical 
mixture EE and EL seemed to be a superposition of the 
spectra of the two polymers and no new peaks were observed 
suggesting that only minimum, if any, interaction could be 
found between EE and EL in their powdered base forms. On 
the other hand, the FT-IR spectrum of the physical mixture 
EE and EL granules seemed to exhibit a shift in the 
absorption peak from 1728 cm-1 to about 1620 cm-1, and 
minimization or disappearance of the absorption peaks at 
2769 and 2823 cm-1 compared to the pure polymers. These 
shifts and minimization in absorption peaks could be 
explained by the ionization of carboxylic acids in EL 
polymer, and the protonation of dimethylamino groups of EE 
polymer [15, 35]. However, despite these changes in the FT-
IR spectra of EE-EL granules compared to the powdered 
mixtures, there was no evidence of any interaction between 
the two polymers in the dry granules mixture. 
 
4. CONCLUSION 
         The combination of anionic and cationic 
polymethacrylate polymers in their salt (individual granules) 
at 1:1 ratio and at total polymers concentrations of 5% was 
found to be effective in extending the release of model acidic 
and basic drugs from matrix tablets. For Ibuprofen, the drug 
release rates from such matrices were decreased when 
shifting the pH values from acidic to neutral compared to 
plain Ibuprofen tablets. For Metronidazole, the drug release 
rates from such matrices were significantly lowered in both 
acidic and neutral media compared to plain metronidazole 
tablets. The polymeric combinations in their salt forms were 
found superior in extending release throughout the 
dissolution profile of model acidic and basic drugs as 
compared to single polymers in their free or salt forms, and 
to the polymeric combinations in their free forms that were 
either directly compressed as powders or granulated using 
isopropyl alcohol. It appears that upon dissolution, a possible 
formation of an interaction between polymeric salts of EE 
and EL with characteristics different from the individual 
polymers is the basis for the significant drug release 
extension. . 
The current findings along with the previously reported work 
suggests  that the combination of EE with EL or with ES in 
their salt form could be suitable for formulating matrix 
tablets for drugs of different physicochemical properties. 
Therefore, such a polymeric combination has the potential to 
be used as a universal carrier for controlling the release of 
drugs from matrix tablets. 
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Table 1a 
 
 
 
 
Name 
Formula No. 
IB1 IB2 IB3 IB4 IB5 IB6 IB7 IB8 
mg/tab %(w/w) mg/tab %(w/w) mg/tab %(w/w) mg/tab %(w/w) mg/tab %(w/w) mg/tab %(w/w) mg/tab %(w/w) mg/tab %(w/w) 
Ibuprofen 400 80 400 80 400 80 400 80  400 80 400 80 400 80 400 80 
Lactose 97.5 19.5 72.5 14.5 72.5 14.5 47.5 9.5 72.5 14.5 47.5 9.5 72.5 14.5 72.5 14.5 
Mg stearate 1.25 0.25 1.25 0.25 1.25 0.25 1.25 0.25 1.25 0.25 1.25 0.25 1.25 0.25 1.25 0.25 
Talc 1.25 0.25 1.25 0.25 1.25 0.25 1.25 0.25 1.25 0.25 1.25 0.25 1.25 0.25 1.25 0.25 
EE   25 5         12.5 2.5 25 5 
EL     25 5 50 10         
ES         25 5 50 10 12.5 2.5 25 5 
Total (mg) 500 100 500 100 500 100 500 100 500 100 500 100 500 100 550 100 
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Table 1b 
 
 
 
 
Name 
Formula No. 
IB9 IB10 IB11 IB12 IB13 IB14 IB15 IB16 
mg/tab %(w/w) mg/tab %(w/w) mg/tab %(w/w) mg/tab %(w/w) mg/tab %(w/w) mg/tab %(w/w) mg/tab %(w/w) mg/tab %(w/w) 
Ibuprofen 400 80 400 80 400 80 400 80 400 80 400 80 400 80 400 80 
Lactose 72.5 14.5 72.5 14.5 72.5 14.5 72.5 14.5 72.5 14.5 72.5 14.5 72.5 14.5 72.5 14.5 
Mg stearate 1.25 0.25 1.25 0.25 1.25 0.25 1.25 0.25 1.25 0.25 1.25 0.25 1.25 0.25 1.25 0.25 
Talc 1.25 0.25 1.25 0.25 1.25 0.25 1.25 0.25 1.25 0.25 1.25 0.25 1.25 0.25 1.25 0.25 
EE-HCl   25a 5     12.5 d 2.5 12.5d 2.5 25a 5 25a 5 
EL-Na     25b 5   12.5 e 2.5   25a 5   
ES-Na       25c 5   12.5f 2.5   25c 5 
EE-IPA 12.5 2.5               
ES-IPA 12.5 2.5               
H2O   q.s  q.s  q.s q.s  q.s    q.s   
Total (mg) 500 500 500 100 500 100 500 500 100 500 100 100 100 500 100 100 
   (a) Equivalent to 17.20 mg of EE       (b) Equivalent to 19.70 mg of EL (c) Equivalent to 19.70 mg of ES             
 (d) Equivalent to 8.60 mg of EE         (e) Equivalent to 9.85 mg of EL (f) Equivalent to 9.85 mg of ES   
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Table 2a 
 
 
 
Name 
Formula No. 
MD1 MD2 MD3 MD4 MD5 MD6 MD7 MD8 MD9 
mg/tab %(w/w)  mg/tab %(w/w) mg/tab %(w/w) mg/tab %(w/w) mg/tab %(w/w) mg/tab %(w/w) mg/tab %(w/w) mg/tab %(w/w) mg/tab %(w/w) 
Metronidazole 400 80 400 80 400 80 400 80 400 80 400 80 400 80 400 80 400 80 
Lactose 85 17 60 12 60 12 35 7 60 12 35 7 60 7 35 7 60 12 
Methocel 12.5 2.5 12.5 2.5 12.5 2.5 12.5 2.5 12.5 2.5 12.5 2.5 12.5 2.5 12.5 2.5 12.5 2.5 
Mg stearate 1.25 0.25 1.25 0.25 1.25 0.25 1.25 0.25 1.25 0.25 1.25 0.25 1.25 0.25 1.25 0.25 1.25 0.25 
Talc 1.25 0.25 1.25 0.25 1.25 0.25 1.25 0.25 1.25 0.25 1.25 0.25 1.25 0.25 1.25 0.25 1.25 0.25 
 
EE 
  25 5         12.5 2.5 25 5   
 
EL 
    25 5 50 10     12.5 2.5 25 5   
 
ES 
        25 5 50 10       
EE-IPA                 12.5 2.5 
EL-IPA                 12.5 2.5 
Total (mg) 500 100 500 100 500 100 500 100 500 100 500 100 500 100 500 100 500 100 
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Table 2b 
 
 
 
Name 
Formula No. 
MD10 MD11 MD12 MD13 MD14 MD15 MD16 MD17 MD18 
mg/tab %(w/w) mg/tab %(w/w) mg/tab %(w/w) mg/tab %(w/w) mg/tab %(w/w) mg/tab %(w/w) mg/tab %(w/w) mg/tab %(w/w) mg/tab %(w/w) 
Metronidazole 400 80 400 80 400 80 400 80 400 80 400 80 400 80 400 80 400 80 
Lactose 60 12 60 12 60 12  60 12 60 12 60 12 60 12 60 12 60 12 
Methocel 12.5 2.5 12.5 2.5 12.5 2.5 12.5 2.5 12.5 2.5 12.5 2.5 12.5 2.5 12.5 2.5 12.5 2.5 
Mg stearate 1.25 0.25 1.25 0.25 1.25 0.25 1.25 0.25 1.25 0.25 1.25 0.25 1.25 0.25 1.25 0.25 1.25 0.25 
Talc 1.25 0.25 1.25 0.25 1.25 0.25 1.25 0.25 1.25 0.25 1.25 0.25 1.25 0.25 1.25 0.25 1.25 0.25 
EE-HCl 25a 5         12.5f 2.5 25a 5 12.5f 2.5 25a 5 
EL-Na   25b 5 50c 10     12.5g 2.5 25b 5     
ES-Na       25d 5 50e 10     12.5h 2.5 25d 5 
H2O q.s  q.s  q.s  q.s  q.s  q.s  q.s  q.s  q.s  
Total (mg) 500 100 500 100 525 100 500 100 525 100 500 100 525 100 500 100 525 100 
 (a) Equivalent to 17.20 mg of EE       (b) Equivalent to 19.70 mg of EL (c) Equivalent to 39.40 mg of EL         (d) Equivalent to 19.70 mg of ES          
 (e) ) Equivalent to 39.40 mg of ES     (f) Equivalent to 8.60 mg of EE (g) Equivalent to 9.85 mg of EL           (h) Equivalent to 9.85 mg of ES  
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Table 3 
 
 
 
 
IB 
Formula # 
Crushing 
strength 
 (Kp)  
Tablet 
thickness 
(mm) 
Tablet 
diameter 
(mm) 
MD 
Formula # 
Crushing 
strength 
 (Kp)  
Tablet 
thickness 
(mm) 
Tablet 
diameter 
(mm) 
IB#1 5.6±0.1 3.41±0.01 12.97±0.08 MD#1 12.1±0.5 2.82±0.03 12.97±0.08 
IB#2 4.9±0.2 3.69±0.01 12.98±0.06 MD#2 11.4±0.5 2.84±0.03 13.08±0.07 
IB#3 4.8±0.2 3.54±0.02 13.09±0.06 MD#3 11.3±0.2 2.80±0.02 13.05±0.05 
IB#4 4.2±0.2 3.57±0.01 13.02±0.06 MD#4 10.2±0.4 2.82±0.02 13.06±0.06 
IB#5 6±0.2 3.53±0.01 13.02±0.06 MD#5 9.4±0.4 2.80±0.02 12.95±0.12 
IB#6 5.5±0.3 3.64±0.02 12.98±0.12 MD#6 11.8±0.6 2.86±0.03 13.05±0.10 
IB#7 9.8±0.3 3.63±0.01 13.04±0.10 MD#7 11.6±0.7 2.88±0.03 12.97±0.05 
IB#8 12±0.4 3.54±0.01 13.02±0.05 MD#8 12.0±1.3 2.87±0.04 12.98±0.11 
IB#9 9.8±0.4 3.64±0.01 12.98±0.11 MD#9 8.8±0.5 2.83±0.02 13.09±0.07 
IB#10 8.4±0.4 3.46±0.02 13.04±0.07 MD#10 12.1±0.5 2.82±0.03 13.02±0.05 
IB#11 11±0.1 3.49±0.03 13.05±0.08 MD#11 11.4±0.5 2.84±0.03 13.02±0.08 
IB#12 10.2±0.4 3.57±0.02 13.06±0.05 MD#12 11.3±0.2 2.80±0.02 12.98±0.06 
IB#13 11.7±0.3 3.56±0.02 12.95±0.06 MD#13 10.2±0.4 2.82±0.02 13.04±0.06 
IB#14 11.5±0.3 3.58±0.01 13.04±0.06 MD#14 9.4±0.4 2.80±0.02 12.98±0.12 
IB#15 11.2±0.5 3.56±0.02 13.04±0.06 MD#15 9.5±0.4 2.82±0.02 12.97±0.12 
IB#16 11.5±0.4 3.57±0.01 13.04±0.06 MD#16 9.8±0.2 2.87±0.02 12.94±0.07 
    MD#17 9.2±0.4 2.86±0.02 13.02±0.12 
    MD#18 9.6±0.2 2.87±0.04 13.02±0.14 
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Table 4 
IB 
Formula # Formula Composition 
Mean 
AUC SD 
Ratio of Mean 
AUC** values p-value 
IB#1 Plain IB  62.98 2.65 1  ---- 
IB#2 IB-EE 5% 62.24 2.45 1.332064298 0.006 
IB#3 IB-EL 5% 60.68 3.22 1.037903757 0.655 
IB#4 IB-EL 10% 25.07 2.78 2.512165935 0.00007 
IB#5 IB-ES 5% 15.08 3.25 4.176392573 0.00004 
IB#6 IB-ES 10% 14.26 2.66 4.41654979 0.00005 
IB#7 IB-EE 2.5%+ES 2.5%  50.85 3.88 1.238544739 0.011 
IB#8 IB-EE 5%+ES 5%  47.9 4.22 1.314822547 0.006 
IB#9 IB-EE-IPA 2.5%+ES-IPA 2.5% 42.15 1.78 1.494187426 0.004 
IB#10 IB-EEHCl 5% 47.28 2.66 1.331188946 0.006 
IB#11 IB-ELNa 5%  14.96 1.21 4.209893048 0.00004 
IB#12 IB-ESNa 5% 26.36 2.78 2.3892261 0.00007 
IB#13 IB-EEHCl 2.5%+ELNa 2.5%  27.65 3.34 2.277757685 0.00006 
IB#14 IB-EEHCl 2.5%+ESNa 2.5%  29.32 2.96 2.148021828 0.00006 
IB#1 (pH 6.8) Plain IB  23.41 2.44 2.690303289 0.00005 
IB#13 (pH 6.8) IB-EE-HCl 2.5%+EL-Na 2.5% 7.53 0.87 8.363877822 0.000006 
MD#1 Plain MD  4.03 0.39 1  ----- 
MD#2 MD-EE 5% 4.24 0.48 0.9504717 0.588 
MD#3 MD-EL 5% 4.11 0.44 0.98053528 0.825 
MD#4 MD-EL 10% 3.95 0.33 1.02025316 0.97 
MD#5 MD-ES 5% 4.15 0.55 0.97108434 0.773 
MD#6 MD-ES 10% 4.09 0.44 0.98533007 0.868 
MD#7 MD-EE 2.5% EL 2.5%  10.97 1.56 0.36736554 0.002 
MD#8 MD-EE 5% EL 5%  10.38 1.68 0.38824663 0.003 
MD#9 MD-EE-IPA 2.5%+EL-IPA  3.63 0.85 1.11019284 0.499 
MD#10 MD-EE-HCl 5% 3.59 0.24 1.12256267 0.447 
MD#11 MD-ELNa 5% 7.28 1.01 0.55357143 0.007 
MD#12 MD-ELNa 10% 10.42 1.88 0.38675624 0.002 
MD#13 MD-ESNa 5% 7.78 1.22 0.51799486 0.008 
MD#14 MD-ESNa 10% 11.83 2.2 0.34065934 0.004 
MD#15 MD-EEHCl 2.5%+ELNa 2.5% 22.2 2.15 0.18153153 0.0007 
MD#16 MD-EEHCl 5%+ELNa 5% 22.05 1.88 0.18276644 0.0008 
MD#17 MD-EEHCl 2.5%+ESNa 2.5% 22.3 2.81 0.18071749 0.0008 
MD#18 MD-EEHCl 5%+ESNa 5% 22.3 2.65 0.18071749 0.0008 
MD#1 (pH 1.2) Plain MD 3.53 0.62 1.14164306 0.445 
MD#1 (pH 6.8) Plain MD 3.59 0.81 1.12256267 0.432 
MD#15 (pH 1.2) MD-EEHCl 2.5%+ELNa 2.5% 10.36 1.14 0.38899614 0.003 
MD#15 (pH 6.8) MD-EEHCl 2.5%+ELNa 2.5% 21.45 3.87 0.18787879 0.0008 
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List of Figures 
Figure 1: Chemical structures of Eudragit E (a), Eudragit L and Eudragit S (b), Ibuprofen (c), and 
Metronidazole (d). 
 
Figure 2. pH dissolution profiles at 50 rpm and 37 oC of IB#3, IB#4, IB#5 and IB#6 tablets compared to 
that of IB#1 tablets, all compressed at 500 Kg. The profile was at pH 1.2, 4.8, and 6.8 as indicated on 
graph. 
 
Figure 3. pH dissolution profiles at 50 rpm and 37 oC of IB#11 and IB#12 tablets compared to that of 
IB#1 tablets, all compressed at 500 Kg. The profile was at pH 1.2, 4.8, and 6.8 as indicated on graph. 
 
Figure 4. pH dissolution profiles at 50 rpm and 37 oC of MD#4, MD#6, MD#11, MD#12, MD#13 and 
MD#14 tablets compared to that of MD#1 tablets, all compressed at 5000 Kg. The profile was at pH 1.2, 
4.8, and 6.8 as indicated on graph. 
 
Figure 5. pH dissolution profiles at 50 rpm and 37 oC of IB#7, IB#13, IB#14 and IB#9 compared to that of 
IB#1 tablets, all compressed at 500 Kg. The profile was at pH 1.2, 4.8, and 6.8 as indicated on graph. 
 
 
Figure 6. pH dissolution profiles at 50 rpm and 37 oC of MD#7, MD#15, MD#17 and MD#9 tablets 
compared to that of MD#1 tablets, all compressed at 5000 Kg. The profile was at pH 1.2, 4.8, and 6.8 as 
indicated on graph. 
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Figure 7. Dissolution at 50 rpm and 37 oC, of IB#13 compared to that of IB #1 tablets in 0.1 N HCl (pH 
1.2) and in phosphate buffer (pH 6.8), all compressed at 500 Kg.  
 
 
Figure 8. Dissolution at 50 rpm and 37 oC of MD#15 compared to that of MD#1 tablets in 0.1 N HCl (pH 
1.2) and in phosphate buffer (pH 6.8), all compressed at 5000 Kg.  
 
 
Figure 9. DSC thermograms for plain Ibuprofen (IB), individual polymers: Eudragit®L100 (EL) and 
Eudragit®E100 (EE), mixtures of IB and Eudragit®L100 (IB-EL 1:1), mixtures of IB and Eudragit®E100 
(IB-EE) at various ratios (1:1, 2:1 and 1:2), and mixtures of IB and Eudragit®E100-HCl (IB-EE HCl 1:1). 
 
 
Figure 10. FT-IR spectra of pure EE and EL powdered polymers (EL-POW and EE-POW), physical mix 
of EE and EL (EE-EL-POW), and physical mixture of EE and EL granules (EE-EL-GR). All physical 
mixtures were at 1:1 ratios. 
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